🦴 Bone Health Panel

What this panel can settle, and by what logic

Bone loss is silent and this panel is not looking for it. It is looking for the correctable reasons a density scan comes back low, which is a different and much cheaper question. Two pairings carry it.

1. Vitamin D (25-Hydroxy) read with Parathyroid Hormone & Calcium, and the threshold is measured rather than asserted. Across 64,979 apparently healthy adults, parathyroid hormone plateaued above a 25-hydroxyvitamin D of 55 nmol/L, about 22 ng/mL, and rose steeply below 22 nmol/L, about 9 ng/mL Gong 2023. A low vitamin D with a PTH at the top of its interval is secondary hyperparathyroidism pulling calcium out of bone; the same low vitamin D with a mid-range PTH is not doing that yet.
2. PTH read against calcium separates the two hyperparathyroidisms. A high PTH with a high calcium is primary, a gland driving itself, and it goes to an endocrinologist. A high PTH with a low or normal calcium is secondary, usually to vitamin D deficiency or to kidney disease, and it is the one a supplement fixes Bertoldo 2022. Creatinine on the Comprehensive Metabolic Panel (CMP) is what tells those two apart, and the PTH interval only means what it says in somebody who is vitamin D replete Gong 2023.

The turnover markers, Osteocalcin among them, answer a third question: whether bone is being broken down faster than it is being rebuilt right now, which a density scan taken once cannot answer at all Bhattoa 2025.

What it cannot settle, and what would

It cannot measure bone density, and density is the thing that breaks. Bone mineral density is measured by DEXA. The international consensus on bone turnover markers places them in monitoring and fracture-risk assessment, not in diagnosis Bhattoa 2025, and a clean result here does not cancel a scan in anyone with a fragility fracture, long-term steroid use or years without a period.

It cannot diagnose osteoporosis, because osteoporosis is defined on a T-score. No combination of calcium, PTH, vitamin D and turnover markers produces one Bhattoa 2025.

One turnover marker is close to uninterpretable in one person. These markers carry substantial biological and pre-analytical variation, which is why the consensus is written around standardized sampling and change over time rather than a single value Bhattoa 2025. The same marker before treatment and 3 months into it is a real measurement; one on its own is not.

And it does not check the commonest secondary causes of bone loss. Hyperthyroidism, hypogonadism, celiac disease and myeloma all thin bone, and this panel carries no test for any of them. A TSH (Thyroid-Stimulating Hormone), an Estradiol, Sensitive (LC/MS-MS) or Total Testosterone, and celiac serology are the next $80 — not a repeat of this Bertoldo 2022.

Draw conditions that decide whether the money is wasted

The turnover markers here are the most draw-sensitive numbers on this site, and getting them wrong is invisible: the result still looks like a result.

1. Morning and fasted, and the same way every time. Bone resorption markers have a marked circadian rhythm and are suppressed by food, which is why the consensus specifies standardized fasting morning collection Bhattoa 2025. A mid-afternoon sample after lunch cannot be read against a fasted morning interval and cannot be compared with a fasted morning result 6 months later.
2. Hold calcium and vitamin D supplements for 24 hours. A dose taken that morning raises serum calcium transiently and suppresses PTH, which turns this panel's central pairing into a picture of breakfast Bertoldo 2022.
3. No biotin for 3 days. PTH and 25-hydroxyvitamin D are both run as streptavidin-based immunoassays on the common analyzers Li 2020, so a single hair supplement moves two of the four numbers that matter here.
4. Treat the vitamin D result as having a tolerance. In the Vitamin D Standardization Program's own study all 12 assays met the imprecision criterion but only 9 of 12 stayed inside ±5% mean bias Wise 2021, so 29 ng/mL and 32 ng/mL from two laboratories are the same result and not a trend.

How you would know it answered your question, and what each pattern means next

Four patterns, and the timescale each runs on. None of them is measured in weeks, because bone is not.

• Vitamin D (25-Hydroxy) under 22 ng/mL with PTH in the top quarter of its interval: the correctable pattern this panel exists to find. Replace, then retest both at 12 weeks rather than 4 — 25-hydroxyvitamin D has a circulating half-life of weeks, so a new steady state is a 3-month event Bertoldo 2022. PTH should settle as vitamin D crosses about 22 ng/mL Gong 2023.
• High PTH with a high calcium on the Comprehensive Metabolic Panel (CMP): not a supplement problem. Primary hyperparathyroidism needs an endocrinologist and imaging, and more vitamin D will not fix it Bertoldo 2022.
• Raised turnover markers with normal mineral chemistry: the panel has done its job and the next test is a DEXA scan, not another panel Bhattoa 2025.
• Everything normal with a fracture history: book the scan anyway, because blood was never going to answer that question. Where these markers do earn their place is afterwards: once treatment starts, a fall in a resorption marker at 3 months is the earliest evidence available that it is working Bhattoa 2025.

Sources read for these sections

• Gong M, et al. Threshold of 25(OH)D and consequently adjusted parathyroid hormone reference intervals: data mining for relationship between vitamin D and parathyroid hormone. Journal of Endocrinological Investigation 2023 · PMID 36920734
• Bertoldo F, et al. Definition, Assessment, and Management of Vitamin D Inadequacy: Suggestions, Recommendations, and Warnings from the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS). Nutrients 2022 · PMID 36235800
• Bhattoa HP, et al. Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Osteoporosis International 2025 · PMID 40152990
• Wise SA, et al. Vitamin D Standardization Program (VDSP) intralaboratory study for the assessment of 25-hydroxyvitamin D assay variability and bias. Journal of Steroid Biochemistry and Molecular Biology 2021 · PMID 34010687
• Li D, Ferguson A, Cervinski MA, Lynch KL, Kyle PB. AACC Guidance Document on Biotin Interference in Laboratory Tests. J Appl Lab Med 2020 · PMID 32445355